Close Menu

NEW YORK – Becton Dickinson and BioGX announced Friday that they received Emergency Use Authorization from the US Food and Drug Administration for a hospital SARS-CoV-2 test.

The rapid test is for hospital use on site to screen patients and healthcare workers and offers results in less than three hours from nasopharyngeal and oropharyngeal swabs. BioGX's test will run on the BD Max system, which processes 24 samples at once. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
12
Sponsored by
Combinati

This webinar will discuss a recent study that characterized the relationships between SARS-CoV-2 RNAemia and disease severity, clinical deterioration, and extrapulmonary complications (EPCs).

May
18
Sponsored by
Bio-Rad

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.  

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.